| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC23851 | AZD 0424 | AZD 0424 is an orally bioavailable small molecule tyrosine kinase inhibitor of Abl and Src kinase with potential antineoplastic activity.. |
|
| DC20720 | AZD 1678 | AZD 1678 is a potent, selective orally bioavailable CCR4 receptor antagonist with pIC50 of 8.6 for hCCR4, pIC50 of 9.0 for rCCR4. |
|
| DC23588 | AZD 3043 | AZD 3043 (THRX-918661) is a positive allosteric modulator of the GABAA receptor in vitro and a sedative/hypnotic agent in vivo, potentiates GABAA receptor-mediated chloride currents with EC50 of 36 uM. |
|
| DC8658 | AZD3264 | AZD 3264 is an IkB-kinase IKK2 Inhibitor, IKK2 has been identified as one of the novel pathways to treat inflammatory conditions such as asthma, chronic pulmonary obstructive disorder (COPD) and rheumatoid arthritis. |
|
| DC20726 | AZD 4205 Featured | AZD 4205 (AZD4205) is a potent, selective JAK1 inhibitor IC50 of 73 nM and Ki of 2.8 nM, shows high selectivity against JAK2 and JAK3 with IC50 of 13,233 nM and >30,000 nM respectively; shows potent inhibition of p-STAT3 in a cell based assay of JAK1 activity with an IC50 of 128 nM and excellent selectivity across the kinome; reduces residual disease and prolongs the benefit of Osimertinib in lung cancer patients with EGFR activating mutations both in vitro and in vivo. |
|
| DC20729 | AZD 5991 Featured | AZD 5991 (AZD5991) is a potent and selective macrocyclic inhibitor of Mcl-1 with sub-nanomolar affinity. |
|
| DC23722 | AZD 6610 | AZD 6610 is a dual peroxisome proliferator-activated receptor (PPAR) α/γ agonist for treatment of diabetes mellitus.. |
|
| DC20730 | AZD 7009 | AZD 7009 is a novel antiarrhythmic agent that inhibits the late sodium current in CHO K1 cells expressing hNav1.5 with IC50 of 11 uM. |
|
| DC9309 | AZD-0156 Featured | AZD-0156 is an orally bioavailable ataxia telangiectasia mutated (ATM) kinase inhibitor, with potential chemo-/radio-sensitizing and antineoplastic activities. |
|
| DC20002 | AZD-0284 Featured | AZD0284 is an inverse agonist of the nuclear receptor RORγ. In development for the treatment of plaque psoriasis vulgaris and respiratory tract disorders. |
|
| DC11481 | AZD-0364 Featured | AZD-0364 is a potent and selective ERK2 inhibitor extracted from patent WO2017080979A1, compound example 18, has an IC50 of 0.6 nM. |
|
| DC20718 | AZD-0837 | AZD-0837 is a novel oral anticoagulant that after bioconversion to its active form is a potent and reversible thrombin inhibitor, has been investigated in phase II studies for prevention of stroke and systemic embolic events in patients with atrial fibril |
|
| DC10534 | AZD0865(Linaprazan) Featured | AZD0865 is a potent agent that inhibits gastric H(+),K(+)-ATPase activity and acid formation in vitro, with a fast onset of effect. |
|
| DC5054 | AZD1080 Featured | AZD1080 is a selective, orally active, brain permeable GSK3 inhibitor, inhibits human GSK3α and GSK3β with Ki of 6.9 nM and 31 nM, respectively, shows >14-fold selectivity against CDK2, CDK5, CDK1 and Erk2. |
|
| DC23670 | AZD-1092 | AZD-1092 (GKA-80) is a potent Glucokinase (GK) activator with EC50 of 30 nM. |
|
| DC7060 | AZD1152 Featured | AZD1152 (barasertib), pro-drug of barasertib-hQPA, is a selective Aurora B kinase inhibitor, AZD1152 inhibited the proliferation various types of human leukemia cells with an IC50 ranging from 3 nM to 40 nM. |
|
| DC5012 | AZD-1208 Featured | AZD1208 is orally available, small molecule inhibitor of PIM kinases with potential antineoplastic activity. |
|
| DC9731 | AZD1283 Featured | AZD1283 is a potent antagonist of the P2Y12 receptor with EC50 of 3.0 ug/kg/min, TI >10; with binding IC50 of 11 nM. |
|
| DC20719 | AZD-1305 | AZD-1305 is a novel antiarrhythmic agent that predominantly blocks the rapid component of IKr, the L-type calcium current, and the inward sodium current in mammalian cells and ventricular cardiomyocytes. |
|
| DC20162 | AZD1390 Featured | AZD1390 is a first-in-class orally available and CNS penetrant ATM inhibitor with an IC50 of 0.78 nM in cells and >10,000-fold selectivity over closely related members of the PIKK family of enzymes and excellent selectivity across a broad panel of kinases |
|
| DC5032 | AZD1480 Featured | AZD1480 is a novel ATP-competitive JAK2 inhibitor with IC50 of 0.26 nM, selectivity against JAK3 and Tyk2, and to a smaller extent against JAK1. Phase 1/2. |
|
| DC7572 | AZD1981 Featured | AZD1981 is a potent, selective CRTh2 (DP2) receptor antagonist with IC50 of 4 nM, showing >1000-fold selectivity over more than 340 other enzymes and receptors, including DP1 |
|
| DC7073 | AZD2014 | AZD2014 is a novel mTOR inhibitor with IC50 of 2.8 nM; highly selective against multiple PI3K isoforms (α/β/γ/δ). |
|
| DC10724 | AZD2098 Featured | AZD2098 is a potent CC-chemokine receptor 4 (CCR4) inhibitor, used for asthma research. |
|
| DC1037 | AZD2461 Featured | AZD2461 is a novel PARP inhibitor with potential to bypass Pgp-mediated resistance to Olaparib. |
|
| DC7748 | AZD-26(AKT-IN-1） Featured | AZD-26 is an inhibitor of AKT. AZD-26 inhibits the phosphorylation of Thr308 on AKT in BT474 cells with an IC50 of 422 nM. |
|
| DC11847 | AZD2716 | AZD2716(AZD-2716) is a novel potent, selective, orally bioavailable sPLA2 inhibitor with excellent plasma sPLA2 inhibition (IC50=0.1 nM). |
|
| DC6302 | AZD2858 Featured | AZD2858 is a selective GSK-3 inhibitor with an IC50 of 68 nM, activating Wnt signaling, increases bone mass in rats. |
|
| DC20050 | AZD2906 | AZD2906 is a selective glucocorticoid receptor (GR) agonist, with IC50s of 2.2, 0.3, 41.6 and 7.5 nM at GR in human, rat PBMC and human, rat whole blood, respectively. AZD2906 increases micronucleated immature erythrocytes (MIE) in the bone marrow of rats |
|
| DC7799 | AZD2932 Featured | AZD-2932 is a high affinity inhibitor of VEFGR-2 and PDGFR. |
|
